Monoamine Oxidase and Head-Twitch Response in Mice Mechanisms of α-Methylated Substrate Derivatives

NeuroToxicology

Volumn 25, Issue 1-2, 2004, Pages 223-232

  Nakagawasai, Osamu ^a   Arai, Yuichiro ^b   Satoh, Shin Etsu ^a   Satoh, Nobunori ^c   Neda, Mitsuro ^a   Hozumi, Masato ^a   Oka, Ryusho ^a   Hiraga, Hajime ^a   Tadano, Takeshi ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Mice; Monoamine oxidase; Neurotransmitters

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5 FLUORO ALPHA METHYLTRYPTAMINE; 5 HYDROXYTRYPTOPHAN; 5 METHOXY N,N DIMETHYLTRYPTAMINE; 6 FLUORO ALPHA METHYLTRYPTAMINE; AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE DERIVATIVE; CINANSERIN; CLORGYLINE; DEXFENFLURAMINE; EPLIVANSERIN; ESTAZOLAM; FENCLONINE; LYSERGIDE; MESCALINE; METHYSERGIDE; METITEPINE; MONOAMINE OXIDASE INHIBITOR; PARGYLINE; PHENINDIONE; PIPERAZINE DERIVATIVE; QUIPAZINE; RIMONABANT; SAFRAZINE; SEROTONIN; TRANYLCYPROMINE; TRIAZOLAM; TYRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOPICLONE;

ANXIETY; BRAIN SYNAPTOSOME; CATECHOLAMINE SYNTHESIS; DRUG HYDROXYLATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HALLUCINATION; HEAD TWITCH; HEART DISEASE; HUMAN; METHYLATION; NERVE ENDING; NONHUMAN; PREFRONTAL CORTEX; PRESSOR RESPONSE; PRIORITY JOURNAL; RAPHE NUCLEUS; RECEPTOR AFFINITY; RECEPTOR BINDING; REVIEW; SEROTONIN RELEASE; SEROTONIN UPTAKE; SEROTONINERGIC NERVE CELL; SYNAPSE VESICLE; WEIGHT REDUCTION;

GYMNOMYZA SAMOENSIS;

EID: 0348046383     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(03)00101-3     Document Type: Article

References (74)

1. Abell CW, Kwan SW. Molecular characterization of monoamine oxidases A and B. Prog Nucl Acid Res Mol Biol 2001;65:129-56.
2. Anderson MC, Hasan F, McCrodden JM, Tipton KF. Monoamine oxidase inhibitors and the cheese effect. Neurochem Res 1993;18:1145-9.
3. Arai Y. Influence of diabetes on monoamine oxidase in rat brain. Biogenic Amines 1992;8:413-20.
4. Arai Y, Toyoshima Y, Kinemuchi H. Studies on monoamine oxidase and semicarbazide-sensitive amine oxidase. Part II. Inhibition by alpha-methylated substrate-analogue monoamines, alpha-methyltryptamine, alpha-methylbenzylamine and two enantiomers of alpha-methyl-benzylamine. Jpn J Pharmacol 1986;41:191-7.
5. Arai Y, Kim SK, Kinemuchi H, Tadano T, Satoh S, Satoh N et al. Inhibition of brain type A monoamine oxidase and 5-hydroxytryptamine uptake by two amphetamine metabolites, p-hydroxyamphetamine and p-hydroxynorephedrine. J Neurochem 1990;55:403-8.
6. Arai Y, Kim SK, Kinemuchi H, Tadano T, Satoh S, Satoh N et al. Selective inhibition of MAO-A in serotonergic synaptosomes by two amphetamine metabolites, p-hydroxyamphetamine and p-hydroxynorephedrine. Neurochem Int 1990;17:587-92.
7. Ask AL, Fagervall I, Ross SB. Selective inhibition of monoamine oxidase in monoaminergic neurons in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1983;324:79-87.
8. 2 receptor stimulation in rats. Neuropharmacology 1996;35:295-301.
9. Bilkei-Gorzo A, Gyertyan I, Levay G. m-CPP-induced anxiety in the light-dark box in rats - a new method for screening anxiolytic activity. Psychopharmacology 1998;136:291-8.
10. Cases O, Seif I, Grimsby J, Gaspar P, Chen K, Poumin S et al. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAO-A. Science 1995;268:1763-6.
11. 1C serotonin receptors. Mol Pharmacol 1992;42:627-33.
12. 2 receptor-mediated behaviors in Sardinian alcohol-preferring rats. Pharmacol Biochem Behav 1995;51:21-7.
13. Dall'Olio R, Vaccheri A, Gandolfi O, Roncada P, Montanaro N. Neuroleptic-induced reduction of quipazine-elicited head-twitches in rats: possible involvement of striatal dopaminergic supersensitivity. Pharmacol Biochem Behav 1988;31:941-4.
14. 2 receptors? Pharmacol Biochem Behav 1990;36:901-6.
15. Darmani NA. Differential potentiation of L-tryptophan-induced head-twitch response in mice by cocaine and sertraline. Life Sci 1996;59:1109-19.
16. Darmani NA. Cocaine and selective monoamine uptake blockers (sertraline, nisoxetine, and GBR 12935) prevent the D-fenfluramine-induced head-twitch response in mice. Pharmacol Biochem Behav 1998;60:83-90.
17. 1 receptor antagonist SR 141716A in naïve mice. J Neural Transm 2000;107:931-45.
18. 1A receptor agonists in the mouse. Br J Pharmacol 1993;109:1046-52.
19. Feldman JM, Henderson JH, Durham MD. Monoamine oxidase, catechol-O-methyltransferase, and norepinephrine levels in mice with the hereditary obese-hypergycemic syndrome. Diabetes 1978;27:389-95.
20. Florvall L, Ask AL, Ögren SO, Ross SB. Selective monoamine oxidase inhibitors. Part 1. Compounds related to 4-aminophenethylamine. J Med Chem 1978;21:56-63.
21. Freedman DX, Gottieb R, Lovell RA. Psychotomimetic drugs and brain 5-hydroxytryptamine metabolism. Biochem Pharmacol 1970;19:1181-8.
22. Freo U, Holloway HW, Greig NH, Soncrant TT. Chronic treatment with meta-chlorophenylpiperazine (m-CPP) alters behavioral and cerebral metabolic responses to the serotonin agonists m-CPP and quipazine but not 8-hydroxy-2-(di-N-propylamino)tetralin. Psychopharmacology 1992;107:30-8.
23. 2 serotonin receptors: evidence for a lack of selectivity. J Med Chem 1992;35:734-40.
24. Goldstein M, Anagnoste B. The conversion in vivo of D-amphetamine to (+)p-hydroxynorephedrine. Biochim Biophys Acta 1965;107:166-8.
25. Goldstein M, Contrera JF. The substrate specificity of phenylamine-β-hydroxylase. J Biol Chem 1962;237:1898-902.
26. 2A,C receptor agonist (+/-)1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Neuropsychobiology 1998;37:36-40.
27. Heal DJ, Cheetham SC, Prow MR, Martin KF, Buckett WR. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br J Pharmacol 1998;125:301-8.
28. Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL et al. Activation of central melanocortin pathways by fenfluramine. Science 2002;297:609-11.
29. Janoyan JJ, Crim JL, Darmani NA. Reversal of SR141716A-induced head-twitch and ear-scratch responses in mice by Δ9-THC and other cannabinoids. Pharmacol Biochem Behav 2002;71:155-62.
30. Kim JJ, Shih JC, Chen K, Chen L, Bao S, Maren S et al. Selective enhancement of emotional, but not motor, learning in monoamine oxidase A-deficient mice. Proc Natl Acad Sci USA 1997;94:5929-33.
31. Kinemuchi H, Arai Y. Selective inhibition of monoamine oxidase A and B by two substrate-analogues, 5-fluoro-α-methyltryptamine and p-chloro-β-methyl-phenylethylamine. Res Commun Chem Pathol Pharmacol 1986;54:125-8.
32. Kinemuchi H, Fowler CJ, Tipton KF. Substrate specificities of the two forms of monoamine oxidase. In: Tipton KF, Dostert P, Strolin Benedetti M, editors. Monoamine oxidase and disease. New York: Academic Press; 1984. p. 53-62.
33. Law MY, Slawson MH, Moody DE. Selective involvement of cytochrome P450 2D subfamily in in vivo 4-hydroxylation of amphetamine in rat. Drug Metab Dispos 2000;28:348-53.
34. Livingston MG, Livingston HM. Monoamine oxidase inhibitors: an update on drug interactions. Drug Saf 1996;14:219-27.
35. Lucki I, Eberle KM, Minugh-Purvis N. The role of the aural head shake reflex in serotonin-mediated head shaking behavior. Psychopharmacology 1987;92:150-6.
36. Malick JB, Doren E, Barnett A. Quipazine-induced head-twitch in mice. Pharmacol Biochem Behav 1977;6:325-9.
37. 2 receptor. Pharmacol Biochem Behav 1997;56:417-22.
38. Mejia JM, Ervin FR, Baker GB, Palmour RM. Monoamine oxidase inhibition during brain development induces pathological aggressive behavior in mice. Biol Psychiatry 2002;52:811-22.
39. Miskiewicz M, Rokosz-Pelc A, Vetulani J. The effect of quipazine and LSD on monoamines in the rat striatum. Pol J Pharmacol Pharm 1979;31:489-92.
40. Nabeshima T, Yamaguchi K, Ishikawa K, Furukawa H, Kameyama T. Potentiation in phencyclidine-induced serotonin-mediated behaviors after intracerebroventricular administration of 5,7-dihydroxytryptamine in rats. J Pharmacol Exp Therp 1987;243:1139-46.
41. Nakagawasai O, Tadano T, Arai Y, Hozumi S, Oba A, Tan-No K, et al. Enhancement of 5-hydroxytryptamine-induced head-twitch response after olfactory bulbectomy. Neuroscience 2003;117:1017-23.
42. 2A/2C agonist. J Med Chem 1994;37:4346-51.
43. Niemegeers CJE, Colpaert FC, Leysen JE, Awouters F, Janssen PAJ. Mescaline-induced head-twitches in the rat: an in vivo method to evaluate serotonin S2 antagonists. Drug Dev Res 1983;3:123-35.
44. Oreland L, Arai Y, Stenstrom A. Age, alcohol, diseases and human brain. In: Tipton KF, Dostert P, Strolin Benedetti M, editors. Monoamine oxidase and disease. New York: Academic Press; 1984. p. 291-300.
45. Orikasa S, Kisara K. A possible mechanism of the tyramine-induced head-twitch response. Eur J Pharmacol 1982;80:163-9.
46. Orikasa S, Sakurada S, Kisara K. Head-twitch response induced by tyramine. Psychopharmacology 1980;67:53-9.
47. Oyama K, Tadano T, Kisara K, Arai Y, Kinemuchi H. Behavioral and biochemical effects of p-hydroxyamphetamine on central monoamine neurons. Jpn J Pharmacol 1989;49:335.
48. Popova NK, Vishnivetskaya GB, Ivanova EA, Skrinskaya JA, Seif I. Altered behavior and alcohol tolerance in transgenic mice lacking MAO-A: a comparison with effects of MAO-A inhibitor clorgyline. Pharmacol Biochem Behav 2000;67:719-27.
49. Raiteri M, Carmine RD, Bertolline A, Levi G. Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline. Eur J Pharmacol 1977;41:133-43.
50. Raiteri M, Bonanno G, Vallebuona F. In vitro and in vivo effects of D-fenfuramine: no apparent relationship between 5-hydroxytryptamine release and hypophagia. J Pharmacol Exp Therp 1995;273:643-9.
51. Reyes-Parada M, Scorza MC, Silveira R, Dajas F, Costa G, Tipton KF et al. Monoamine oxidase inhibitory effects of some 4-aminophenethylamine derivatives. Biochem Pharmacol 1994;47:1365-71.
52. Rubino T, Vigano D, Zagato E, Sala M, Parolaro D. In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments. Synapse 2000;35:8-14.
53. Sakurada S. Central action of β-phenylethylamine derivatives. Part 6. Head-twitches induced by intracerebrally administered tyramine in isocarboxazide pretreated mice. Folia Pharmacol Jpn 1975;71:779-87.
54. Sandler M, Glover V, Ashford A, Stern GM. Absence of "cheese effect" during deprenyl therapy: some recent studies. J Neural Transm 1978;43:209-15.
55. Sandler M, Glover V, Ashford A, Esmail A. The inhibition of tyramine oxidation and the tyramine hypertensive response ("cheese effect") may be independent phenomena. J Neural Transm 1980;48:241-7.
56. Satoh S, Satoh N, Tadano T, Kisara K. Enhancement of parahydroxyamphetamine induced head-twitch response by catecholamine depletion. Res Commun Sub Abuse 1985;6:213-9.
57. Shah NS, Jacobs JR, Jones JT, Hedden MP. Interaction of mescaline with phenothiazines: effect on behavior, body temperature, and tissue levels of hallucinogen in mice. Biol Psychiatry 1975;10:561-73.
58. Shih JC. Molecular basis of human MAO-A and -B. Neuropsychopharmacology 1991;4:1-7.
59. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci 1999;22:197-217.
60. Singleton C, Marsden CA. Circadian variation in the head-twitch response produced by 5-methoxy-N1, N1-dimethyltryptamine and p-chloroamphetamine in the mouse. Psychopharmacology 1981;74:173-6.
61. Sloviter RS, Drust EG, Connor JD. Specificity of a rat behavioral model for serotonin receptor activation. J Pharmacol Exp Therp 1978;206:339-47.
62. Tadano T, Satoh S, Kisara K. Head-twitches induced by p-hydroxyamphetamine in mice. Jpn J Pharmacol 1986;41:519-23.
63. Tadano T, Satoh S, Satoh N, Kisara K, Arai Y, Kinemuchi H. Involvement of α-adrenoceptors in para-hydroxyamphetamine-induced head-twitch response. Neuropharmacology 1987;26:1463-7.
64. Tadano T, Satoh S, Satoh N, Kisara K, Arai Y, Kim SK et al. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain. J Pharmacol Exp Therp 1989;250:254-60.
65. Tadano T, Neda M, Hozumi M, Yonezawa A, Arai Y, Fujita H et al. Alpha-methylated tryptamine derivatives induce a 5-HT receptor-mediated head-twitch response in mice. Neuropharmacology 1995;34:229-34.
66. Tadano T, Hozumi M, Satoh N, Oka R, Hishinuma T, Mizugaki M et al. Central serotonergic mechanisms on head-twitch response induced by benzodiazepine receptor agonists. Pharmacology 2001;62:157-62.
67. Taylor WA, Sulser F. Effect of amphetamine and its hydroxylated metabolites on central noradrenergic mechanisms. J Pharmacol Exp Therp 1973;185:620-32.
68. Tipton KF. Monoamine oxidase inhibition. Biochem Soc Trans 1994;22:764-8.
69. Trulson ME, Brandstetter JW, Crisp T, Jacobs BL. Behavioral effects of quipazine in the cat. Eur J Pharmacol 1982;78:295-305.
70. Walker SE, Shulman KI, Tailor SA, Gardner D. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J Clin Psychopharmacol 1996;16:383-8.
71. Wang H, Grahame-Smith DG. The effects of rubidium, caesium and quinine on 5-HT-mediated behaviour in rat and mouse. Part 3. Quinine. Neuropharmacology 1992;31:425-31.
72. 2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Therp 1997;282:699-706.
73. Yamamoto T, Ueki S. The role of central serotonergic mechanisms on head-twitch and backward locomotion induced by hallucinogenic drugs. Pharmacol Biochem Behav 1980;14:89-95.
74. Yamamoto T, Ohno M, Yatsugi S, Fujikawa Y, Ueki S. Nootropic candidates inhibit head-twitches induced by mescaline in mice. Jpn J Pharmacol 1992;59:419-21.